IPL 550260
Alternative Names: IPL 550,260Latest Information Update: 07 Feb 2017
Price :
$50 *
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 07 Feb 2017 Discontinued - Phase-I for Inflammation in Canada (PO)
- 17 Mar 2006 Suspended - Phase-I for Inflammation in Canada (PO)
- 13 Jul 2004 Inflazyme has completed phase Ib studies in inflammation in Canada